Clinical trials: High-risk
Glioma, Medulloblastoma
Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.
- Trial name
- NCT00404495
- Testing
- Irinotecan, Temozolomide
- Where
- 29 sites in Australia, Belgium and 6 more
- Volunteers
- 83 people
- Sponsor
- Pfizer
Metastatic Colorectal Cancer
Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.
The purpose of this study is to evaluate the safety and efficacy of the experimental drug abituzumab (EMD525797) in combination with cetuximab and FOLFIRI in RAS wild-type, left-sided, metastatic colorectal cancer patients with…
- Trial name
- AMELION (NCT03688230)
- Testing
- abituzumab
- Sponsor
- SFJ Pharmaceuticals X, LTD.
Healthy
Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.
The objective of the current study is to investigate safety, tolerability, and pharmacokinetics of treatment with BI 661051 rising single doses administered as oral drinking solution (powder in bottle) in healthy male subjects.
- Trial name
- NCT01343719
- Testing
- BI 661051
- Where
- Germany
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Skin Thickness
Echographic Measurement of Skin Thickness
To optimize a medical device for intradermal injection, knowledge concerning the thickness of epidermis and dermis at the proximal forearm is required.
- Trial name
- NCT02363465
- Testing
- Echographic measurement of skin thickness
- Where
- Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Novosanis NV
Hypercholesterolemia, Familial
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high…
- Trial name
- NCT00134511
- Testing
- Torcetrapib/atorvastatin
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 30 people
- Sponsor
- Pfizer
Exercise Performance Recovery
The Effect of XSurge Supplementation on Biomarkers and Performance From High Intensity Resistance Exercise
Part one of this study will consist of baseline (BL) testing, 28 days of daily supplementation with XSurge, and an exercise protocol.
- Trial name
- NCT02442245
- Testing
- XSurge, Control: No supplementation
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Ovarian Cancer
A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer
The purpose of this study is to determine the objective response rate of ABT-888 when given in combination with temozolomide versus pegylated liposomal doxorubicin (PLD) alone in subjects with recurrent high grade serous ovarian…
- Trial name
- NCT01113957
- Testing
- ABT-888, pegylated liposomal doxorubicin, temozolomide
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 168 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
High-grade Squamous Intraepithelial Lesion (HSIL)
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
This is a randomized, double-blind, placebo controlled Phase 2 study to determine the efficacy and safety of NWRD09 administered by intramuscular (IM) injection in adult women with histologically confirmed cervical high grade…
- Trial name
- NCT07712692
- Testing
- NWRD09 Injection
- Where
- 15 sites in China
- Volunteers
- 156 people
- Sponsor
- Newish Biotech (Wuxi) Co., Ltd.
Hypertension
Effectiveness and Tolerability of Tarka® in the Treatment of Hypertensive Patients With High Risk of Developing Diabetes Mellitus
The aim of this post-marketing observational study (PMOS) is to provide data on the effectiveness and tolerability of Tarka in patients with a high risk of developing diabetes mellitus, as prescribed by the physicians in a…
- Trial name
- TARDIA (NCT01079195)
- Where
- 898 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 15,436 people
- Sponsor
- Abbott
Disease Related Malnutrition
Effect of Plant Based High Energy High Protein Oral Nutritional Supplement on Nutritional Intake in Patients With or at Risk of Disease Related Malnutrition.
The subjects will use study product twice daily for 8 weeks starting at Visit 1. The recommendation is to consume one serving in the morning and one in the afternoon / evening between meals.
- Trial name
- PRO-PLANT (NCT06781619)
- Testing
- Test Product: Plant based high energy high protein ONS, Control Product: Dairy based high energy high protein ONS
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 76 people
- Sponsor
- Nutricia Research
Acute Myeloid Leukemia
A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
This study evaluated the efficacy and safety of midostaurin in combination with daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single agent continuation therapy in newly diagnosed patients…
- Trial name
- NCT03280030
- Testing
- Midostaurin
- Where
- 34 sites in Hong Kong, Japan and 4 more
- Volunteers
- 67 people
- Sponsor
- Novartis Pharmaceuticals
Cardiac Output, High, Cardiac Output, Low
Using Minimally Invasive Cardiac Output Data vs. Standard Care for Patients Emergently Admitted to the Intensive Care Unit Who Are Hemodynamically Unstable
The purpose of this study is to evaluate if the continuous availability of minimally invasive cardiac output data during treatment in the intensive care unit (ICU) for hemodynamic instability, in comparison to standard of care…
- Trial name
- NCT00354211
- Testing
- minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)
- Where
- 3 sites in Finland, Switzerland
- Volunteers
- 392 people
- Sponsor
- Edwards Lifesciences
Healthy, Epilepsy
Bridging Gaps in the Neuroimaging Puzzle: New Ways to Image Brain Anatomy and Function in Health and Disease Using Electroencephalography and 7 Tesla Magnetic Resonance Imaging
The human brain presents outstanding challenges to science and medicine. Brain function and structure span broad spatial scales (from single neurons to brain-wide networks) as well as temporal scales (from milliseconds to years).
- Conditions
- Healthy, Epilepsy, Psychosis, Essential Tremor
- Trial name
- NCT05769933
- Testing
- Simultaneous EEG-fMRI at 7 Tesla, Structural MRI at 7 Tesla
- Where
- Switzerland
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Critical Illness
A Open Study to Evaluate the Performance of Dressing on Subject With High Risk of Skin Breakdown
The rational for the study is to add a thin self-adherent dressing on critically ill patients. Evaluate if the dressing might protect the skin for further breakdown.Participants will be followed for the duration of hospital stay…
- Trial name
- NCT01354899
- Where
- Sweden
- Volunteers
- 24 people
- Sponsor
- Molnlycke Health Care AB
High-grade Glioma, Lung Cancer
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
This proof-of-concept study is designed to assess the ability of [18F]AH-111585 PET imaging to detect tumors and angiogenesis. Up to 30 evaluable subjects are planned to be included at up to 2 study centers in the US.
- Conditions
- High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma
- Trial name
- NCT00565721
- Testing
- Fluciclatide Injection - (AH111585 (F18))
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- GE Healthcare
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention
Early Feasibility Study of the Supira System in Patients Undergoing HRPCI
The objective of this study is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI.
- Conditions
- Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
- Trial name
- NCT06087575
- Testing
- Supira System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Supira Medical
CIN 2/3, HPV Infection
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia
- Trial name
- ART-CIN_IIB (NCT04098744)
- Testing
- Artesunate vaginal insert
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Frantz Viral Therapeutics, LLC
High-Risk Multidisciplinary Care, Clinical Decision Support
ANCHOR Validation Trial in High-Risk Multidisciplinary Care
This pre-registered, pragmatic, three-arm (1:1:1) patient-level randomized controlled trial with mixed-effects analysis at the encounter level tests two questions in real high-risk multidisciplinary clinical encounters at the…
- Conditions
- High-Risk Multidisciplinary Care, Clinical Decision Support, Artificial Intelligence-Assisted Care, Telemedicine
- Trial name
- NCT07597499
- Testing
- Gemini 3.1 Pro with Safety Prompt, ANCHOR Clinical AI Verification Layer (with Gemini 3.1 Pro)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Waymark
Primary Immunodeficiency Disease
High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)
This was a prospective, open-label, non-controlled, non-randomized multicenter Phase III study of 2 multiple-dose intravenous NewGam regimens (every 3 weeks or every 4 weeks, continuing the patient's infusion interval in the main…
- Trial name
- NGAM-05 (NCT01313507)
- Testing
- NewGam
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Octapharma
Hemophilia A
Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
This is a first-in-human, non-randomized, open label, single treatment, Phase 1 study in approximately 7 patients with severe hemophilia A.
- Trial name
- NCT04418414
- Testing
- Gene therapy, Biological
- Volunteers
- 7 people
- Sponsor
- Expression Therapeutics, LLC